Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by houbahopon Jan 11, 2022 8:29pm
160 Views
Post# 34306290

RE:RE:Next annual meeting vote will be interesting.

RE:RE:Next annual meeting vote will be interesting.You're absolutely right, SPCEO1! I have skipped a year.

Here are the results of 2021 Annual sahreholders meeting.
It will be interesting to see if there is a trend forming:

As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and elected KPMG LLP, as the Company’s auditors for the current fiscal year.

All candidates proposed for the position of directors were elected in the following proportion:

  #
IN FAVOUR
%
IN FAVOUR
#
ABSTENTION
%
ABSTENTION
         
Joseph Arena 36,236,725 94.13 2,259,788 5.87
Grald A. Lacoste 29,952,972 77.81 8,543,541 22.19
Paul Lvesque 36,788,358 95.56 1,708,155 4.44
Gary Littlejohn 29,029,970 75.41 9,466,543 24.59
Andrew Molson 33,682,560 87.50 4,813,953 12.50
Alain Trudeau 33,722,300 87.60 4,774,213 12.40
Dawn Svoronos 34,243,837 88.95 4,252,676 11.05
Dale MacCandlish-Weil 33,663,747 87.45 4,832,766 12.55

Dawn Svoronos, Chair of the Board and Paul Lvesque, President and CEO of Theratechnologies, addressed people who attended the virtual meeting.


<< Previous
Bullboard Posts
Next >>